



SEE AND TREAT

Endoscopic Intervention with Olympus

Interventional endoscopy has undergone rapid development. Many patients who would have required surgery not long ago can be easily treated via endoscopic therapy now.

EMR, ESD, POEM, and stenting are only a few chapters of a success story that gastroenterologists like you are writing every day. With innovative endoscopic technologies – such as Dual Focus and NBI, coupled with a range of perfectly matched endotherapy instruments – Olympus provides you with the tools you need to provide targeted and effective treatment.

Discover more today at www.olympus-europa.com.



Figures: Courtesy of the Asklepios Klinik in Hamburg Barmbek



November 6 and 7, 2015

Congress Center Hamburg

President: Thomas Rösch

Friedrich Hagenmüller
Siegbert Faiss

VERTRAUEN DURCH KLARHEIT

MOVIPREP®

IHR PARTNER IN DER
ERFOLGREICHEN DARMVORBEREITUNG.
EFFEKTIV - VERTRÄGLICH - COMPLIANT¹



MOVIPREP®

PEG + ASC (PEG (3350) + Sodium ascorbate
+ Ascorbic acid + Sodium sulfate + Electrolytes)



1. Ell C. et al. American Journal of Gastroenterology 2008; 103(4):883-893.

MOVIPREP®/MOVIPREP® ORANGE, Pulver zur Herstellung einer Lösung zum Einnehmen

Zusammensetzung: Beutel A enthält: Macrogol 3350 100 g, Natriumsulfat 7,5 g, Natriumchlorid 2,691 g, Kaliumchlorid 1,015 g; Beutel B enthält: Ascorbinsäure 4,7 g, Natriumascorbat 5,9 g, Hilfsstoffe MOVIPREP®: Aspartam, Acesulfam-Kalium, Zitronenaroma. Hilfsstoffe MOVIPREP® ORANGE: Aspartam, Acesulfam-Kalium, Orangenaroma. **Anwendungsgebiete:** Zur Darmvorbereitung vor klinischen Maßnahmen, die einen sauberen Darm erfordern, z.B. endoskopische oder radiologische Untersuchungen des Darms. **Gegenanzeigen:** Gastrointestinale Obstruktion oder Perforation, Störungen der Magenentleerung, Ileus, Phenylketonurie, Glukose-6-Phosphatdehydrogenase-Mangel, Überempfindlichkeit gegen die Wirkstoffe oder die sonstigen Bestandteile, toxisches Megakolon als Komplikation schwerer entzündlicher Darmerkrankungen. MOVIPREP®/MOVIPREP® ORANGE darf nicht bei bewussten Patienten angewendet werden. **Nebenwirkungen:** Sehr häufig: Abdominalschmerz, Übelkeit, abdominale Aufblähung, Anreizungen, Unwohlsein. Häufig: Schlafstörungen, Schwindel, Kopfschmerzen, Erbrechen, Dyspepsie, Rigor, Durst, Hunger. Gelegentlich: Dysphagie, Leberfunktionstests anormal, Unbehagen. Nicht bekannt: Anaphylaxie, Krampfanfälle im Rahmen einer ausgeprägten Hyponatriämie, vorübergehender Anstieg des Blutdrucks, Flatulenz, Brechreiz, Pruritus, Urticaria, Hautausschlag, Elektrolytverschiebungen einschließlich Bikarbonatkonzentration im Blut vermindert, Hyper- und Hypocalcämie, Phosphatkonzentration im Blut vermindert, Hypokaliämie und Hyponatriämie (die beiden letztgenannten Störungen treten häufiger bei Patienten auf, die gleichzeitig Medikamente einnehmen, die einen Einfluss auf die Niere haben, wie z.B. ACE-Inhibitoren und Diuretika) sowie Änderungen der Chloridkonzentration im Blut. **Handelsformen:** Eine Anwendung besteht aus 2 Btl. A und 2 Btl. B. Packungsgrößen von 1 (N 1), 10, 40, 80, 160 und 320 Packungen einer einzelnen Anwendung. Klinikpackung mit 40 einzelnen Anwendungen. Apothekenpflichtig. Stand 07/2012



MOVIPREP, NORGINE and the sail logo are registered trademarks of the Norgine Group of companies.

TABLE OF CONTENTS

ENDOCLUBNORD 2015

Foreword	5
Program NEW: Workshops on Friday	6
Experts	9
General Information	16
Registration	17
Travel	19
Cooperation with Deutsche Bahn (German Railway)	20
Cooperation with Lufthansa Group Partner	21
Public Transportation – HVV-Map	23
City Map	25
Sponsors	27
Registration Form	29

Scientific Chairman and
responsible for the editorial
content:

Prof. Dr. Thomas Rösch
Universitätsklinikum
Hamburg-Eppendorf

Design and Layout



COCSMEDIA

Rosenheimer Str. 145c · 81671 Munich, Germany
www.cocs-media.de



Download Program

COCS media does not guarantee
the correctness of information.

Distribution supported by Olympus Europa Holding GmbH.



Zur Darmreinigung vor Koloskopien oder Röntgenuntersuchungen

Für eine gründliche Entleerung und Reinigung¹

- Duales Wirkprinzip durch zwei Wirkstoffe¹
- Hohe Patientenverträglichkeit²
- Schmeckt angenehm nach Zitrone³



¹ Fachinformation CitraFleet® Stand 12/2010

² Cidarriz A, et al. Calidad de la colonoscopia: efectividad y tolerancia de tres regímenes de limpieza. Poster presented at Semana de las Enfermedades Digestivas (SED) 11-14 de Junio, 2011. Sevilla, Spain.

³ Schirin-Sokhan R., Trautwein C., MMW Fortschritte der Medizin Originalien 2009; 151(1): 34-38

CitraFleet® Pulver zur Herstellung einer Lösung zum Einnehmen in einem Beutel. Wirkstoffe: Natriumpicosulfat, leichtes Magnesiumoxid, wasserfreie Citronensäure. **Zusammensetzung:** 1 Beutel mit 15,08 g Pulver enth. 10,0 mg Natriumpicosulfat, 3,5 g leichtes Magnesiumoxid und 10,97 g wasserfreie Citronensäure. Sonst. Bestandt.: Kaliumhydrogencarbonat, Saccharin-Natrium, Zitronenaroma (Zitronenaroma, Maltodextrin, RRR- α -tocopherol E 307). **Anwendungsgebiete:** für Erwachsene ab 18 Jahren: zur Darmreinigung vor jeder diagnostischen Untersuchung, die nur bei einem gut gereinigten Darm sinnvoll durchgeführt werden kann (z.B. Koloskopie, Röntgen). **Gegenanzeigen:** Überempf. gg. Bestandt., dekomp. Herzinsuff., schwere Dehydrat., Hypermagnesiemie, Magenretention, Ulzerat. GIT, tox. Colitis, tox. Megacolon, Ileus, Übelkeit, Erbrechen, Aszitis, Appendizitis, Obstr./Perfor. GIT, Rhabdomyolyse, aktive Entzündung (Morbus Crohn, Colitis ulcerosa), eingeschr. Nierenfunkt. **Warnhinweise:** enthält 5 mmol Kalium. **Nebenwirkungen:** sehr häufig: Bauchschm. häufig: Schlafst., Kopfschm., Mundtrock., Übelkeit, Blähbauch, Analbeschw., Proktalgie, Durstgef., Müdigk., gelegentlich: Schwindel, orthostat. Hypot., Erbrechen, Stuhlinkont., Häufigk. n. bekannt: Anaphylaktoide Reakt., Überempf., Hyponatriämie, Epilepsie, Grand-mal-Anfall, Konvuls., Verwirrheitszust., Durchfall, Flatulenz, Hautausschl., Urikaria, Pruritus, Purpura, Schmerzen. **Apothekenpflichtig.** Stand: April 2012. **Zulassungsinhaber:** Laboratorios Casen-Fleet S.L.U., Autovia de Logroño Km 13,300, 50180 UTEBO, Zaragoza, Spanien. **Mitvertreiber:** Recordati Pharma GmbH, Eberhard-Finckh-Str. 55, 89075 Ulm.



RECORDATI PHARMA



PD Dr. Siegbert Faiss Prof. Dr. Thomas Rösch Prof. Dr. Friedrich Hagenmüller

Welcome to the 23rd ENDOCLUBNORD!

Dear guests and endoscopy experts,

We look forward to welcoming you to the 23rd ENDOCLUBNORD in Hamburg on November 6 and 7, 2015. Again this year, we will be demonstrating the latest developments in flexible gastroenterological endoscopy. This ENDOCLUBNORD will focus in particular on interfaces between endoscopy and histopathology as well as minimally invasive surgery. You will be able to see many exciting live cases, followed by case discussions on Saturday. For the first time, Friday evening will be finished with high-class workshops with possibilities to get direct answers to all your questions.

Gastrointestinal pathology has always been our gold standard essentially backing up diagnostic endoscopy. The exciting development of endoscopic imaging, resulting in super-high resolutions and details, allows us to view structures that almost seem to match tissue diagnosis. We also have a long and fruitful relationship with minimally invasive surgery, another area where we see continuous progress. We wish to work on and discuss all these questions with you.

Come to Hamburg, Germany's premiere location for endoscopy, on November 6 and 7! We look forward to seeing you there!

Siegbert Faiss

Asklepios Klinik
Barmbek

Thomas Rösch

President 2015
Universitätsklinikum
Hamburg-Eppendorf

Friedrich Hagenmüller

Asklepios Klinik
Altona

9.00 – 9.15 a.m.	Opening and Introduction <i>President: Thomas Rösch, Hamburg</i> <i>Honorary President: Manfred Stolte, Kulmbach</i> <i>Honorary Member: Kazuhiro Saito, Tokyo, Japan</i>
9.15 – 10.10 a.m.	Endoscopy live, Part 1 Live Video Broadcast from the three Hospitals: Asklepios Klinik Altona, Asklepios Klinik Barmbek and Universitätsklinikum Hamburg-Eppendorf
10.10 – 10.30 a.m.	IBD – Update 2015: endoscopy, diagnostics, therapy <i>Axel Dignäß, Frankfurt</i> <i>AbbVie Lecture</i>
10.30 – 11.15 a.m.	Endoscopy live, Part 2
11.15 – 11.45 a.m.	Coffee Break in the Industry Exhibition
11.45 – 12.40 p.m.	Endoscopy live, Part 3
12.40 – 01.00 p.m.	Liver cirrhosis – a malignant disease <i>Ansgar Lohse, Hamburg</i> <i>Norgine Lecture</i>
01.00 – 01.50 p.m.	Lunch Break in the Industry Exhibition
01.50 – 02.50 p.m.	Endoscopy live, Part 4
02.50 – 03.10 p.m.	New specific mechanisms in IBD therapy – perspectives <i>Britta Siegmund, Berlin</i> <i>Takeda Lecture</i>
03.10 – 04.00 p.m.	Endoscopy live, Part 5
04.00 – 04.20 p.m.	Coffee Break in the Industry Exhibition
04.20 – 05.00 p.m.	Endoscopy live, Part 6

05.15 – 06.30 p.m.	Workshops und discussions - NEW - Registration required, no extra charge.
	Seminar für Pflege- und Assistenzpersonal Therapeutische Endoskopie <i>Leitung: Hans-Dieter Allescher</i> <i>Teilnehmer: Ute Pfeifer, Rita Hieber, Martin Mangold,</i> <i>Kollegen aus den drei Hamburger Kliniken</i>
	Workshop 1 Advanced polypectomy <i>Chair: Horst Neuhaus</i> <i>Discussants: Dirk Hartmann, Kenneth Binmoeller,</i> <i>Helmut Messmann</i>
	Workshop 2 ERCP – Cannulation, precut and sphincterotomy <i>Chair: Paul Fockens</i> <i>Discussants: Jacques Devière, Alexander Meining,</i> <i>Stefan Seewald</i>
	Workshop 3 Early tumors in esophagus and stomach <i>Chair: Friedrich Hagenmüller</i> <i>Discussants: Oliver Pech, Uwe Seitz, Naohisa Yahagi</i>
	Workshop 4 Overview on Novel Pancreatobiliary Interventions Together with SADE und National Societies Poland, Czech Republic and Hungary <i>Chair: Thomas Rösch</i> <i>Discussants: Lars Aabakken, Jaroslaw Regula,</i> <i>Julius Spicak, István Rác</i>

9.00 – 10.30 a.m.

Friday's Highlights Part 1

Histology, Evidence and Discussion

*Andrea Tannapfel, Bochum**Thomas Rösch, Hamburg**Friedrich Hagenmüller, Hamburg**Siegbert Faiss, Hamburg*

10.30 – 11.00 a.m.

Coffee Break and visit in the Industry Exhibition

11.00 – 11.45 a.m.

Pathology and Endoscopy: Scenes from a Marriage

Barrett esophagus, IBD surveillance, resect and discard strategy, serrated adenomas

*Andrea Tannapfel, Bochum**Gustavo Baretton, Dresden**Michael Vieth, Bayreuth**Thomas Rösch, Hamburg**Friedrich Hagenmüller, Hamburg**Siegbert Faiss, Hamburg*

11.45 – 12.30 p.m.

Friday's Highlights Part 2

Histology, Evidence and Discussion

*Andrea Tannapfel, Bochum**Thomas Rösch, Hamburg**Friedrich Hagenmüller, Hamburg**Siegbert Faiss, Hamburg*

12.30 – 01.00 p.m.

The most interesting cases from 2014 – follow-up

01.00 – 01.15 p.m.

Closing Remarks and Invitation to the

24. ENDOCLUBNORD

November 4 and 5, 2016

**HONORARY PRESIDENT**Prof. Dr. Dr. Manfred Stolte
Kulmbach, Germany**HONORARY MEMBER**Katsuyuki Saito
Tokyo, Japan**FOUNDING PRESIDENT**Prof. Dr. Nib Soehendra
Hamburg, GermanyProf. Dr. Lars Aabakken
Rikshospitalet University
Hospital

Oslo, Norway

Prof. Dr. Hans-Dieter Allescher
Klinikum Garmisch-Partenkirchen

Garmisch-Partenkirchen, Germany

Dr. Jens Aschenbeck
Gastroenterologische
Schwerpunktpraxis

Berlin, Germany

Prof. Dr. Gustavo B. Baretton
Universitätsklinikum Carl Gustav
Carus

Dresden, Germany

Dr. Julia Bertolini
MVZ Hanse Histologikum GmbH

Hamburg, Germany

Prof. Dr. Kenneth Binmoeller
California Pacific Medical Center

San Francisco, California, USA

Prof. Dr. Jacques Devière
Université Libre des Bruxelles
Hôpital Erasme

Brussels, Belgium

Prof. Dr. Axel Dignatz
Agaplesion Markus
Krankenhaus

Frankfurt, Germany

Targeted mesalazine for mild ileocaecal Crohn's disease



- **Targeted release**
in the terminal ileum and colon ascendens
- **High local luminal concentrations**
due to accelerated release
- **Proven efficacy**
in mildly active ileocaecal Crohn's disease¹



Salofalk® Tablets
Mesalazine with Crohn's galenic

Salofalk® Tablets are not approved for Crohn's disease in all countries. Please refer to your local SPC.

* Crohn's Disease Activity Index (CDAI) ≤ 300.
1 Tromm et al., Gastroenterology, 2011;140:425–34

Salofalk® Granules 500mg/1000mg/1.5g/3g; Salofalk® 250mg/500mg Gastro-resistant tablets, Salofalk® 250mg/500mg/1g Suppositories, Salofalk® 2g/30ml and 4g/60ml Enemas; Salofalk® 1g Rectal Foam. Active ingredient: mesalazine (5-aminosalicylic acid). **Composition:** 1 sachet of Salofalk® granules 500mg/1000mg/1.5g/3g contains: active ingredient: 500 mg/1000 mg/1.5 g/3 g mesalazine. Other ingredients: aspartame (E951), carmellose sodium, citric acid, silica colloidal anhydrous, hypromellose, magnesium stearate, methacrylic acid-methyl methacrylate copolymer (1:1) (Eudragit L 100), methylcellulose, cellulose microcrystalline, polyacrylate dispersion 40% (Eudragit NE 40 D containing 2% Nonoxynol 100), povidone K25, simeticone, sorbic acid, talc, titanium dioxide (E171), triethyl citrate, vanilla custard flavouring (containing propylene glycol). 1 tablet of Salofalk® 250mg/500mg contains: active ingredient: 250 mg/500 mg mesalazine. Other ingredients: Calcium stearate, basic butylated methacrylate copolymer (=Eudragit E), methacrylic acid methyl methacrylate copolymer (1:1) (=Eudragit L), glycine, silica colloidal anhydrous, hypromellose, macrogol 6000, cellulose microcrystalline, sodium carbonate anhydrous, povidone K25, talc. Colouring agents: titanium dioxide (E171), iron oxide hydrate (E172), additionally Salofalk® 500mg tablets: croscarmellose sodium. 1 Salofalk® 250mg/500mg/1g suppository contains: active ingredient: 250 mg/500 mg/ 1 g mesalazine. Other ingredients: hard fat; additionally Salofalk® 500mg suppositories: docusate sodium, cetyl alcohol. 1 enema of Salofalk® 2g/30ml or 4g/60ml contains: active ingredient: 2 g or 4 g mesalazine. Other ingredients: sodium benzoate (E211), potassium metabisulphite (E224), potassium acetate, carbomer 947P, sodium edetate, xanthan gum, purified water. Note: Salofalk® enemas contain sodium benzoate and potassium metabisulphite. See patient information leaflet. Salofalk® 1g Rectal Foam: 1 actuation contains: active ingredient: 1 g mesalazine. Other ingredients: sodium metabisulphite (E223), cetostearyl alcohol, polysorbate 60, sodium edetate, propylene glycol. Propellants: propane, n-butane, isobutane. Note: Salofalk® 1g Rectal Foam contains sodium metabisulphite (E223), propylene glycol and cetostearyl alcohol. See patient information leaflet. **Indications:** Salofalk® granules 500mg/1000mg/1.5g/3g: acute treatment and prevention of recurrence of ulcerative colitis. Salofalk® 250mg/500mg tablets: acute treatment and prevention of recurrence of ulcerative colitis. Salofalk® 250mg/500mg/1g suppositories: acute treatment of recurrence of ulcerative colitis. Salofalk® 2g/30ml and 4g/60ml enemas: acute treatment of mild to moderate ulcerative colitis confined to the rectum. Additionally Salofalk® 250mg suppositories: prevention of recurrence of ulcerative colitis. Salofalk® 2g/30ml enemas: acute treatment of mild to moderate ulcerative colitis, localised in the rectum and sigmoid colon. Salofalk® 4g/60ml enemas: acute treatment of ulcerative colitis. Salofalk® 1g Rectal Foam: Treatment of active, mild ulcerative colitis of the sigmoid colon and rectum. **Contraindications:** known hypersensitivity to salicylates or any of the excipients, severe impairment of hepatic or renal function. Pregnancy and lactation: risk-benefit ratio. Additionally for Salofalk® Enemas and Rectal Foam: not to be used in case of sensitive patients (especially for known asthmatics or allergic anamnesis) due to the content of metabisulphite or sodium benzoate. **Side effects:** headaches, dizziness, peripheral neuropathy, abdominal pain, diarrhoea, flatulence, nausea, vomiting, impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency. Hypersensitivity reactions such as allergic exanthema, drug fever, pancolitis, lupus erythematosus syndrome, allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), peri- and myocarditis, acute pancreatitis, myalgia, arthralgia, altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leucopenia, thrombocytopenia), changes in liver function parameters (increase in transaminases and parameters of cholestasis), hepatitis, cholestatic hepatitis, alopecia, oligospermia (reversible). Additionally for Salofalk® 1g Rectal Foam: abdominal distension, anal discomfort, application site irritation, painful rectal tenesmus. Salofalk® 1g Supp.: constipation. **Interactions and dosage:** see patient information leaflet. Available on prescription only. Date of information: 11/2012

DR. FALK PHARMA GmbH



Leinenweberstr. 5
79108 Freiburg
Germany

www.dr-falk-pharma.com

EXPERTS



Dr. Bernd Feyerabend
MVZ Hanse Histologikum
GmbH

Hamburg, Germany



Rita Hieber
Klinikum Augsburg

Augsburg, Germany



Prof. Dr. Ansgar Lohse
Universitätsklinikum
Hamburg-Eppendorf

Hamburg, Germany



PD Dr. Oliver Mann
Universitätsklinikum
Hamburg-Eppendorf

Hamburg, Germany



Prof. Dr. Helmut Messmann
Klinikum Augsburg

Augsburg, Germany



Prof. Dr. Horst Neuhaus
Evangelisches Krankenhaus
Düsseldorf

Düsseldorf, Germany



PD Dr. Dirk Hartmann
Sana Klinikum Lichtenberg
Oskar-Ziethen-Krankenhaus

Berlin, Germany



Prof. Dr. Stephan Hollerbach
Allgemeines Krankenhaus Celle

Celle, Germany



Martin Mangold
Klinikum Garmisch-Partenkirchen

Garmisch-Partenkirchen, Germany



Prof. Dr. Alexander Meining
Universitätsklinikum Ulm

Ulm, Germany



Dr. Gero Moog
Gastroenterologische Fachpraxis

Kassel, Germany




Dr. Gabriele Niemann
HELIOS Klinikum
Emil von Behring


Berlin, Germany

Recently approved in the EU!

A new therapy option to treat Short Bowel Syndrome



Optimizes the absorptive capacity of the intestine^{1,2}



References:

1. Jeppesen et al., Gut 2005;54:1224-1231
2. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM323506.pdf>

All details and the prescribing information can be found at:

www.npsp.de/arzneimittel



NPS Pharma Germany GmbH · The Squire 12,
Am Flughafen · 60549 Frankfurt/Main
Tel: 069 959 325 208 · E-Mail: info@npsp.de



EXPERTS



Dr. Michael Oelckers
Albertinen-Krankenhaus

Hamburg, Germany



PD Dr. Oliver Pech
Krankenhaus Barmherzige
Brüder Regensburg

Regensburg, Germany



Prof. Dr. István Rácz
Petz Aladar County and
Teaching Hospital

Győr, Hungary



Prof. Dr. Hans-Joachim Schulz
Sana Klinikum Lichtenberg

Berlin, Germany



Prof. Dr. Stefan Seewald
Klinik Hirslanden

Zurich, Switzerland



Prof. Dr. Britta Siegmund
Med. Klinik I, Charité
Universitätsmedizin Berlin,
Campus Benjamin Franklin
Berlin, Germany



Prof. Dr. Karl-Jürgen Oldhafer
Asklepios Klinik Barmbek

Hamburg, Germany



Dr. Ute Pfeifer
Evangelisches Krankenhaus
Düsseldorf

Düsseldorf, Germany



Prof. Dr. Jaroslaw Regula
Medical Center for
Postgraduate Education and
Institute of Oncology
Warsaw, Poland



Prof. Dr. Wolfgang Schwenk
Asklepios Klinik Altona

Hamburg, Germany



PD Dr. Uwe Seitz
Kreiskrankenhaus Bergstraße

Heppenheim, Germany



Prof. Dr. Julius Spicak
IKEM -Institute for Clinical
and Experimental Medicine

Prague, Czech Republic

Turn up the volume.

Expand your tissue grasping capabilities with the Instinct Endoscopic Hemoclip. At 16 mm, the jaw span is the widest on the market. And because it is fully adjustable, you can open and close the Instinct clip to securely grasp as much—or as little—tissue as your procedure requires.



For your next clipping procedure, simply follow your instincts to enhanced patient care.



Instinct™
ENDOSCOPIC HEMOCLIP



Dr. Stefan Steurer
Universitätsklinikum
Hamburg-Eppendorf

Hamburg, Germany



Prof. Dr. Andrea Tannapfel
Ruhr-Universität Bochum

Bochum, Germany



Prof. Dr. Katharina Tiemann
MVZ Hanse Histologikum GmbH

Hamburg, Germany



Prof. Dr. Michael Vieth
Klinikum Bayreuth GmbH

Bayreuth, Germany



Prof. Dr. Naohisa Yahagi
Keio University
School of Medicine

Tokyo, Japan

Congress Presidents	Prof. Dr. Thomas Rösch Universitätsklinikum Hamburg-Eppendorf Prof. Dr. Friedrich Hagenmüller Asklepios Klinik Altona PD Dr. Siegbert Faiss Asklepios Klinik Barmbek
Venue	Congress Center Hamburg - CCH Marseiller Straße · 20355 Hamburg, Germany
Congress Organization	COCS GmbH – Congress Organisation C. Schäfer Rosenheimer Str. 145c · 81671 Munich, Germany Phone: +49 (0)89 – 89 06 77-0 Fax: +49 (0)89 – 89 06 77-77 E-mail: sandra.reber@cocs.de · www.cocs.de
	
Opening Hours Registration Desk	Thursday, November 5, 2015 4.00 p.m. – 7.00 p.m. Friday, November 6, 2015 8.00 a.m. – 7.00 p.m. Saturday, November 7, 2015 8.00 a.m. – 2.00 p.m.
Internet	www.endoclubnord.com
Translation	The conference languages are German and English with translation during the main congress.
Certification	Confirmation of participation will be issued to all participants at the end of the congress. The congress will be certified by the Ärztekammer (General Medical Council) Hamburg.
Liability	The congress organizer will bear no liability for loss, accident, damage or injury to persons or property irrespective of the cause. The client participates at all sessions, tours and events at his/her own risk. Sole place of jurisdiction is Munich, Germany. German law is applicable.

Registration fee	payment received by Sep 30, 2015	from Oct 1, 2015
Physician	€ 240,-	€ 280,-
Member bng/ESGE	€ 200,-	€ 240,-
Assistance (evidence enclosed)	€ 70,-	€ 90,-
Nurse	€ 70,-	€ 90,-
Student (evidence enclosed)	€ 70,-	€ 90,-
Team Ticket:		
1 physician and 2 nurses	€ 350,-	€ 390,-
1 physician and 3 nurses	€ 400,-	€ 440,-
1 physician and 4 nurses	€ 430,-	€ 470,-

In the registration fee coffee breaks and lunches are included.

Registration Please register via our website www.endoclubnord.com or complete the enclosed registration form at the end of this program. The final registration date is **November 2, 2015**. After this date on site registration only.

Mode of Payment On your bank transfer please indicate "ECN 2015" and the name of the participant and transfer funds to the following account:

COCS GmbH, Munich, Germany
HypoVereinsbank Munich, Germany
IBAN: DE30 7002 0270 0039 6131 40
SWIFT/BIC: HYVEDEMMXXX
Please note that we do not cover any bank charges.

Congress Documents For payments received before October 20, 2015 by participants from Germany, Austria and Switzerland the personal congress documents will be sent by post before the congress. To avoid unnecessary delays the final conference program and your badge holder will be available in the entrance hall of the CCH.

Cancellation Cancellation in writing must be received no later than October 20, 2015. A service fee of € 20,- will be deducted from the refund amount. Registration fees will not be refunded if cancellations are received at a later date.

**Hotel
Reservation**

Rooms are reserved under www.hrs.de/endoclubnord. Please note that two other big events are taking place in Hamburg at the same time as the ENDOCLUBNORD and hotels will be booked out early.

**SMS/E-mails
to the
moderators**

Questions or comments during the sessions can be sent via SMS: announced on site
E-mail: ecn@luxav.org

**Photography/
filming**

No photography or filming during lectures or live demonstrations permitted. The organizers will share selected recordings on the website. In case you do not wish to be recorded please advise in advance.

by train

The Congress Center Hamburg is right next door to Dammtor InterCity rail station. For further details related to the exclusive German Railways offer for ENDOCLUBNORD participants please see page 20.

by car

If you come to CCH - Congress Center Hamburg by car or motor bike, please follow the signs to "Messe/CCH" from all directions.

parking

The CCH offers parking for € 2,- per hour and € 14,- per day.

**by HVV
(public transport)**

Dammtor station is right next to CCH, for InterCity trains and S-Bahn. U-Bahn stations Stephansplatz (Opera/CCH) and Gänsemarkt are just a short walk away, on a route that passes through a landscaped park and attractive streets. You will be entitled to use Hamburg's entire public transport system for the duration of the conference. The network includes buses, "S-Bahn" (overground trains) and "U-Bahn" (underground metro system) as well as some of the harbour ferries. Your name badge will be valid as your ticket. See map on page 23.



Environment and Climate-Friendly Journey with Deutsche Bahn

Travel by train from Euro 99 with 100% green power to ENDOCLUBNORD

In cooperation with the COCS GmbH and Deutsche Bahn you travel safely and conveniently to ENDOCLUBNORD!

Your way to save the environment: Travel with 100% green power to your event with Deutsche Bahn long-distance services. We guarantee to get the energy you needed for your journey in Germany from 100% renewable sources.

The price for your Event Ticket for a return trip* to Hamburg is:

- 2nd class Euro 99 €
- 1st class Euro 159 €

Our service centre is looking forward to inform you about the ticket price for international journeys. Your ticket is valid from 4th to 9th November 2015.

To book call +49 (0)1806 - 31 11 53** and mention **ENDOCLUBNORD** as reference. Please have your credit card ready when booking. Alternatively, you can also reserve your ticket online at www.bahn.de/Veranstaltungsticket. Your booking will be binding after Deutsche Bahn's confirmation.

Every time you purchase an Event Ticket with your BahnCard or bahn.bonus Card you can collect valuable bonus and status points. Redeem your bonus points by selecting attractive rewards such as free journeys or first-class upgrades. For more information go to www.bahn.de/bahn.bonus

Your price advantages compared to the regular prices***:

e. g. for your journey from (return trip)			1 st class – 159 €		2 nd class – 99 €	
			Regular Fare	Your Price Advantage	Regular Fare	Your Price Advantage
Munich	↔	Hamburg	€460	€301	€284	€185
Frankfurt/M.	↔	Hamburg	€396	€237	€244	€145
Leipzig	↔	Hamburg	€330	€171	€204	€105
Cologne	↔	Hamburg	€314	€155	€194	€95
Berlin	↔	Hamburg	€252	€93	€156	€57

The COCS GmbH and Deutsche Bahn wish you a pleasant journey!

* An advance booking of at least three days is required. Changes and reimbursement before the first day of validity are possible. Changes and reimbursement conditions at the time of the ticket booking are according to Conditions of Carriage of the DB of Sparpreis fares. Changes and reimbursement are excluded from the first day of validity onwards. Passengers restrict themselves to a particular train and travel times. For a supplement of Euro 40 full flexible tickets are also available for domestic travels within Germany.

** The booking line is available from Monday to Saturday 07:00 am to 10:00 pm. Calls will be charged at Euro 0.20 per call, from mobiles Euro 0.60 per call at maximum.

*** Prices are subject to change.

Special offer: Discounted travel with Lufthansa Group Airlines



Lufthansa Group Partner Airlines offer a comprehensive global route network linking major cities around the world. We offer special prices and conditions to participants, visitors, exhibitors, invited guests as well as employees of the Contracting partner and their travel companions.

To make a reservation, please click on:

www.lufthansa.com/event-booking_en and enter the access code **DE-ZEDLO** in the „Access to Your Special Lufthansa Offer“ area. This will open an online booking platform that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

Note: Pop-ups must be enabled otherwise the booking platform window will not open.

These promotional fares are also available through your IATA / ARC travel agent. Travel agents can obtain ticketing instructions by sending an email to lufthansa.mobility@dlh.de and providing the access code as a reference.

GI Solutions - Advancing the Gastrointestinal Care Continuum

GI solutions brings together three innovative companies – Barrx Medical, Beacon Endoscopic and Given Imaging – to offer gastroenterologists a single-destination diagnostic and therapeutic solution covering the GI care continuum.

Partner with GI Solutions to benefit from improved care and outcomes for your patients, effective diagnostic and treatment options, and an efficient system designed to help lower costs.

One

One single solution for the continuous care of patients



Screening



Diagnosing



Treating



Monitoring

Barrx™ RFA System

bnx™ FNA System

Bravo® pH Monitoring System

Digitrapper® pH-Z Monitoring System

ManoScan® HRM System

PillCam® Platform

SmartPill® Motility Monitoring System

Discover more at www.covidien.com/gisolutions

[GI Solutions]



COVIDIEN

positive results for life™

COVIDIEN, COVIDIEN with logo, Covidien logo and *positive results for life* are U.S. and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company.
© 2014 Covidien.

CITY MAP



ELEVATION AND ABLATION USING JUST ONE INSTRUMENT

Barrett ablation using HybridAPC



One instrument for all Barrett localizations and esophagus lumina

Our benefits

- ✦ Waterjet elevation prior to APC ablation
- ✦ Thermal protection of the muscularis
- ✦ Limited APC penetration depth, minimized risk of stricture
- ✦ Targeted, dynamic APC application; healthy epithelium is preserved

Benefits of the HybridAPC probe

- ✦ Cost-effective disposable instrument
- ✦ With proven APC and waterjet functions
- ✦ No instrument change for elevation and ablation



For further information on our complete range of products, visit our home page.

ERBE Elektromedizin GmbH | Tübingen | Telefon +49 7071 755-400 | www.erbe-med.com

ERBE

Perfection for Life

SPONSORS

The ENDOCLUBNORD is grateful for the support of its sponsors:

OLYMPUS

Olympus Deutschland GmbH, Hamburg

abbvie

AbbVie Deutschland GmbH & Co. KG, Wiesbaden



Cook Deutschland GmbH, Mönchengladbach



Covidien Deutschland GmbH, Hamburg



Erbe Elektromedizin GmbH, Tübingen



Dr. Falk Pharma GmbH, Freiburg



marpinion Market Research GmbH, Oberhaching



Micro-Tech Europe GmbH, Düsseldorf



Norgine GmbH, Marburg



NPS Pharma Germany GmbH, Frankfurt am Main



Recordati Pharma GmbH, Ulm



Takeda Pharma Vertrieb GmbH & Co. KG, Berlin

Without engagement - status print date



Next-Generation Communication with Physicians

**HELP MAKE A DIFFERENCE BY
BECOMING AN OPINION LEADER!**

marpinion®: the new approach to communicating with physicians.

Come see us at Endo Club Nord 2015 – your personal iPad is waiting for you! We'll demonstrate our innovative new app and show how you too can benefit from marpinion®. If you like, we'll also be happy to visit you in your practice with no further obligation on your part. Just give us a ring!



marpinion Market Research GmbH | Raiffeisenallee 16 |
82041 Oberhaching | Phone +49 89 1 222 836-800 |
www.marpinion.de | info@marpinion.de

REGISTRATION

Please cut off and send in
a window envelope.

Registration also at:
www.endoclubnord.com

I will participate at the ENDOCLUBNORD 2015

payment received by Sep 30, 2015

from Oct 1, 2015

☐ Physician	€ 240,-	€ 280,-
☐ Member of bng	€ 200,-	€ 240,-
☐ Member of ESGE	€ 200,-	€ 240,-
☐ Assistance (evidence enclosed)	€ 70,-	€ 90,-
☐ Nurse	€ 70,-	€ 90,-
☐ Student (evidence enclosed)	€ 70,-	€ 90,-

Team-Ticket

☐ 1 physician and 2 nurses	€ 350,-	€ 390,-
☐ 1 physician and 3 nurses	€ 400,-	€ 440,-
☐ 1 physician and 4 nurses	€ 430,-	€ 470,-

Name of the nurses attending (last name, first name):

1. _____

2. _____

3. _____

4. _____

NEW:
Workshops
on Friday

I take part on Friday, November 6, 2015, 05.15 p.m. to 06.30 p.m:

- ☐ Seminar für Pflege- und Assistenzpersonal
- ☐ Workshop 1 - Advanced polypectomy
- ☐ Workshop 2 - ERCP – Cannulation, precut and sphincterotomy
- ☐ Workshop 3 - Early tumors in esophagus and stomach
- ☐ Workshop 4 - Overview on Novel Pancreatobiliary Interventions

Please deposit the total amount to the account indicated below:

COCS GmbH, Munich, Germany

HypoVereinsbank München

IBAN: DE30 7002 0270 0039 6131 40 · SWIFT/BIC: HYVEDEMMXXX

Keyword: ECN2015 and name of participant

Please note that we do not cover any bank charges.

Date, Signature



REGISTRATION



Register by post or online: www.endoclubnord.com

COCS GmbH
Congress Organisation C. Schaefer
Rosenheimer Str. 145c
81671 Munich
Germany

☐ Ms. ☐ Mr. ☐ Prof. ☐ PD Dr. ☐ Dr.

Last Name _____
 First Name _____
 Hospital/Institute/Practice _____
 Department _____
 Street _____
 Zip Code _____ City _____
 Area Code _____ Phone _____
 E-mail _____

Statistics: ☐ Office-based physician ☐ Hospital-based physician
 Specialisation: ☐ Gastroenterology ☐ Surgery ☐ Internal medicine ☐ Others



Ulcerative Colitis and Crohn's Disease: **TREAT WITH PRECISION AT THE SITE OF INFLAMMATION**



GUT-SELECTIVE

- Lasting remission¹⁻³
- Good tolerability profile¹⁻³
- The first ever gut-selective integrin receptor antagonist for moderately to severely active ulcerative colitis and Crohn's disease¹⁻⁴

Approved for use in patients following **conventional therapy** or anti-TNF therapy¹

1. Entyvio® Summary of Product Characteristics. 05/2014. 2. Feagan BG, et al. N Engl J Med. 2013; 369(8): 699-710. 3. Sandborn WJ, et al. N Engl J Med. 2013; 369(8): 711-721. 4. Wyant T, et al. Gut. 2014; 0: 1-7. doi: 10.1136/gutjnl-2014-307127

Entyvio® 300 mg powder for concentrate for solution for infusion

Active substance: vedolizumab. Description: *Active ingredient:* Each vial contains 300 mg of vedolizumab; after reconstitution, each mL solution for infusion contains 60 mg vedolizumab. *Excipients:* L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose, polysorbate 80. *Therapeutic indications and posology:* *Ulcerative colitis:* Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. *Crohn's disease:* Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. *Contraindications:* Hypersensitivity to the active substance or to any of its excipients. *Active severe infections* such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML). (see SmPC section 4.4) *Adverse reactions:* *Very common:* nasopharyngitis, headache, arthralgia; *Common:* bronchitis, gastroenteritis, upper respiratory tract infection, influenza, sinusitis, pharyngitis, paresthesia, hypertension, oropharyngeal pain, nasal congestion, cough, anal fissure, nausea, dyspepsia, constipation, abdominal distension, flatulence, haemorrhoids, rash, pruritus, eczema, erythema, night sweats, acne, muscle spasms, back pain, muscular weakness, fatigue, pyrexia; *Uncommon:* respiratory tract infections, vulvovaginal candidiasis, oral candidiasis, folliculitis, infusion site reaction (incl. infusion site pain and infusion site irritation), infusion related reaction chills, shivering, feeling cold. During the second infusion, one case of a serious infusion related reaction was reported by a Crohn's disease patient during the second infusion (symptoms reported were dyspnea, bronchospasm, urticaria, flushing, rash, as well as, increased blood pressure and heart rate) and was managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. *Infections:* In controlled and open-label long-term extension studies in adults with vedolizumab, serious infections have been reported, which include tuberculosis, sepsis (some fatal), salmonella sepsis, listeria meningitis, and cytomegaloviral colitis. *Malignancy:* Overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment. However, the number of malignancies in the clinical trials was small; long-term exposure was limited. Long-term safety evaluations are ongoing. For drug interactions and other information, see SmPC. Prescription only. EU marketing authorisation holder: Takeda Pharma A/S, Taastrup, Denmark. Contact address of the pharmaceutical company in Germany: Takeda GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Tel.: 0800 825 3325, medinfo@takeda.de. 05/2014



© 2014 Takeda Pharma Vertrieb, GmbH & Co. KG

